Barclays »

Theriva Biologics shares owned by Barclays

Quarter-by-quarter ownership of Theriva Biologics (TOVX) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Theriva Biologics

Tip: Access up to 7 years of quarterly data

All positions including Theriva Biologics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Theriva Biologics by Barclays

Quarter filed Position value Share count Share price at filing
2025-12-31 $6.9k 33k 0.21
2024-09-30 $999 495 2.02

More positions owned by Barclays

SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Microsoft Corp Opt Put Option (MSFT)
Apple (AAPL)
Ishares Tr Opt Call Option (IWM)
Alphabet Inc Class A cs (GOOGL)
Amazon (AMZN)
Tesla Motors (TSLA)
Facebook Inc cl a (META)
Broadcom (AVGO)
Alphabet Inc Class C cs (GOOG)
Ishares Tr Opt Put Option (HYG)
Advanced Micro Devices (AMD)
JPMORGAN CHASE &amp Opt Put Option (JPM)

View all positions for Barclays

Top funds holding Theriva Biologics

Vanguard Group
Geode Capital Management
UBS Group
Ikarian Capital
Two Sigma Investments
Two Sigma Securities
DRW Holdings
XTX Topco
Intl Fcstone
Barclays
Boothbay Fund Management
Two Sigma Advisers
Schwarz Dygos Wheeler Investment Advisors
BlackRock
Advisor Group Holdings

View all funds holding Theriva Biologics